The FDA approved a new drug called Zepbound, which activates GLP-1 to help with obstructive sleep apnea, while also resulting ...

ANSWER: “Floaters” are bits of cellular debris in the vitreous humor, which is the gel-filled space in between the lens and ...

A new study adds to a growing body of research suggesting a potential link between popular GLP-1 medications like Ozempic and ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

Beyond treating diabetes and helping people lose weight, GLP-1s may also improve libido. But the reasons are as complex as ...

We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra Investments. In this article, we will ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Analysts expect more than $18 billion in sales from Mounjaro this year and over $10 billion from Zepbound, which was recently ...

ResMed’s strong demand for AirSense 11 boosts its earnings outlook. Learn why RMD stock is undervalued with growth ...

Mounjaro and Zepbound are part of a wave of diabetes ... approved in the United States as a treatment for some forms of sleep apnea. Additional approvals like that and Lilly's push to increase ...